Phase 1 Mesothelioma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older (or the minimum age required by local rules) at the time of signing the consent form
• People who have a laboratory-confirmed diagnosis of a locally advanced, returning, or spread solid tumour of a specific type that has a genetic change called MTAP deletion — including mesothelioma, cancers of the oesophagus or stomach area, pancreatic cancer, bile duct or gallbladder cancer, non-small cell lung cancer (NSCLC), or urothelial (bladder/urinary tract) cancer (the exact tumour types eligible depend on which part of the trial a person is being considered for)
• People who are willing and able to provide blood and tumour tissue samples for testing, including an archived tumour tissue sample to confirm MTAP loss
• People whose cancer shows a specific genetic change — homozygous loss of MTAP or MTAP deletion — confirmed through testing
• People who have at least one tumour that can be measured on a scan, according to standard measurement rules (RECIST v1.1)
• People with a performance status score of 0 or 1 on the standard ECOG scale, meaning they are fully active or have only minor restrictions in physical activity
• People with a life expectancy of more than 3 months
• People with adequate bone marrow and organ function (confirm with trial site)
• People who are able to swallow and keep down tablets or capsules of the study drug
• People who are willing and able to attend all scheduled visits, follow the treatment plan, and complete all study requirements
• People of any sex who are willing to use contraception during the study

For people with NSCLC specifically:

• People whose NSCLC has been confirmed by laboratory testing and has worsened after prior treatment with platinum-based chemotherapy and a type of immunotherapy called a PD-1/PD-L1 inhibitor (unless those treatments were not suitable or not tolerated)
• People who have received no more than 3 prior treatment lines for advanced or metastatic disease
• People whose cancer has a known treatable genetic change must have already received at least one appropriate targeted therapy for that change (unless it was not suitable or not tolerated)

For people with urothelial cancer, mesothelioma, gastroesophageal cancer, pancreatic cancer, or biliary tract cancers specifically:

• People with a laboratory-confirmed diagnosis of one of these cancers in an advanced or metastatic stage
• People whose cancer has worsened after at least one prior treatment
• People who have received no more than 3 prior treatment lines for advanced or metastatic disease

Who may not be able to join:

• People with brain metastases (cancer that has spread to the brain) that are causing symptoms and require high doses of steroid medicines
• People with a cancer that started in the brain or central nervous system
• People who have had another cancer within the past 2 years (some exceptions may apply — confirm with trial site)
• People with significant heart problems or reduced heart function
• People with uncontrolled fluid build-up around the lungs, abdomen, or heart within 2 weeks before the first dose, which requires repeated draining or a permanent drain
• People who have had a serious infection within 4 weeks before starting the study treatment
• People with high blood pressure (above 150/100 mmHg) that cannot be controlled with medication
• People with certain other ongoing or long-term medical or mental health conditions (confirm with trial site)
• People with a weakened immune system or a positive HIV test at screening
• People with known or suspected viral hepatitis confirmed by a positive test at screening
• People who still have side effects from a previous cancer treatment that have not improved to a mild level (Grade 1 or lower on a standard scale)
• People who have recently received certain cancer treatments before the first study dose — including chemotherapy within 4 weeks, immunotherapy or biological treatments within 2 weeks, small molecule inhibitors within 2 weeks, or other experimental treatments within 4 weeks
• People who currently have side effects from radiation therapy, or who received radiation therapy within 2 weeks before the first dose
• People who have taken certain medicines that strongly affect how the body processes drugs (including strong inhibitors or inducers of specific liver enzymes or drug transporters) within 2 weeks before the first dose (confirm full list with trial site)
• People who have used proton pump inhibitors (a type of medicine for stomach acid, such as omeprazole) within 7 days before the first dose, or who plan to use them during the study
• People who have used medicines known to affect heart rhythm (QT prolongation) within 2 weeks before the first dose
• People who have previously been treated with a MAT2A inhibitor or a PRMT inhibitor (specific types of experimental drugs)
• People who have had major surgery within 4 weeks before entering the study
• People who have previously had radiation therapy covering more than 25% of their bone marrow
• People with a known or suspected allergy to the study drug IDE892

Important: Always verify eligibility with the trial site directly before applying.